Annual Report

Overview

The report describes Heidelberg Pharma's continued realignment around its ATAC technology and proprietary development candidate HDP-101. The company made progress toward clinical development, signed an exclusive multi-target research agreement with Takeda, and advanced GMP manufacturing preparations. Two corporate actions secured financing with a 2017 transaction volume of €39.4 million. The company also completed its name change from WILEX AG and relocation to Ladenburg.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2017
Period: 1 December 2016 – 30 November 2017
Publication date: 22 March 2018
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Level
Standard
Scope
Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services